Dowlati, A., Califano, R., Goto, K., Pérol, M., Wu, Y., Boccia, R. V., Fishkin, P. A. S., Hamm, J. T., Jacobs, B., Johnson, M. L., Kunta, G., Nair, S., Patel, M. R., Smith, C. J., Tu, Y., Zhang, J., Zhang, P., Zhou, R., Rodríguez, L. P. (2026). A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps8136